Ranibizumab for the treatment of Age-Related Macular Degeneration related research hotspot and dynamic

Author:

Xiaodong Li1,Xuewei Qin1,Dandan Wu1,Yi Yang2,Zhilin Li3

Affiliation:

1. The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

2. University of Traditional Chinese Medicine

3. Chengdu University of Traditional Chinese Medicine

Abstract

Abstract Objective: Bibliometric analysis in the research area of Ranibizumab and Age-Related Macular Degeneration(AMD) was conducted to describe the current trends in international research dynamics in the field and to present a visual representation of the research hotspots and difficulties in ophthalmic drugs in the last fifteen years. Method: In this cross-sectional study, bibliometrics analyzed data retrieved and extracted from the Web using the Science Core Collection (WOSCC) database to analyze the evolution and thematic trends in the delivery of studies from January 1, 2008, to September 2, 2023, for Ranibizumab and AMD studies. A total of 2691 articles on the field were assessed for specific characteristics such as year of publication, journal, author, institution, country/region, citation and keywords. Co-authorship analysis, co-occurrence analysis, co-citation analysis, and network visualization were constructed using VOSviewer. Bibliometrics identified a number of important sub-themes for further discussion and review of characterization. Results: From 2008 to 2023, the cumulative number of articles published globally increased from 1 to 2,691, with the highest number of articles published in 2020 (255 papers). RETINA THE JOURNAL OF RETINAL AND VITREOUS DISEASES published the most manuscripts (285 papers) and was cited (6,496 citations), followed by OPHTHALMOLOGY (193 papers) and GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (163 papers). OPHTHALMOLOGY was the most cited (20,865 citations), with the United States (786 papers, 38,014 citations), univ sydney (98 papers, 5,245 citations), and kim, jong woo (56 papers, 550 citations) being the most productive and influential institutions, countries, and authors, respectively.Co-occurring clusters: the top 100 keywords analyzed form 5 clusters:Marking the emerging frontiers in the field of ranibizumab and AMD. Further discussion of the 5 clusters of research is to assist the researcher in determining the scope of the research topic and planning the direction of the research. Conclusion:The number of publications and citations of research related to Ranibizumab and AMD has been increasing over the last two decades in many countries, institutions and authors. This study reveals the current trends, global collaboration patterns, basic knowledge, research hotspots and developmental trends in Ranibizumab associated with AMD research. New solutions of Ranibizumab for AMD such as shorter number of injections, prolonged drug efficacy and safety have been the major themes in the last 15 years.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3